

SHUKRA

PHARMACEUTICALS LTD.

06th August, 2022

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai.

Scrip Code: 524632

Dear Sir/Madam,

SUB: - OUTCOME OF BOARD MEETING

With reference to above subject and in compliance with the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 06th August, 2022 at 11:00 a.m. and concluded at 3.30 p.m.:-


- 1) Considered, adopted and approved Unaudited Financial Results for the quarter ended on 30th June, 2022.

You are requested to kindly take the same on record.


Thanking you,

Yours faithfully

For Shukra Pharmaceuticals Limited


Bhoomiben Patel
Director
(DIN: 08316893)

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH June, 2022

		Rs. In Lakhs (Except EPS)			
Sr. No.	Particulars	QUARTER ENDED		Year Ended	
		30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
1	Income from Operations				
I	Revenue from Operations	656.57	893.58	315.79	2,048.60
	(a) Net Sales/ Income from Operations	656.57	893.58	315.79	2,048.60
II	Other Income	0.81	3.71	3.00	8.10
	Total Income from Operations (I+II)	657.38	897.30	318.79	2,056.70
2	Expenses				
	(a) Cost of materials consumed	368.05	531.68	76.11	1,107.99
	(b) Purchase of Stock-in Trade		-	-	
	(c) Changes in inventories of finished goods, and work-in-progress and stock in trade	32.95	(74.94)		(73.41)
	(d) Employee Benefit Expenses	133.73	158.39	103.95	490.45
	(e) Finance Cost	11.54	20.55	1.83	28.66
	(f) Depreciation & Amortisation Expenses	42.15	55.68	36.84	166.21
	(g) Other Expenses	26.45	121.05	95.11	235.00
	Total Expenses	614.87	812.41	313.84	1,954.90
3	Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-2)	42.51	84.88	4.95	101.80
4	Exceptional Items		-	-	-
5	Profit / (Loss) before Extra ordinary items and Tax (3-4)	42.51	84.88	4.95	101.80
6	Extra ordinary items		-	-	-
7	Net Profit / (Loss) from Ordinary Activities before Tax(5-6)	42.51	84.88	4.95	101.80
8	Tax Expenses				
	I. Current Tax	9.04	15.68	1.24	17.58
	II. Deferred Tax	0.68	0.98	-	5.62
	II. Tax of Earlier Year		3.53		3.53
	IV. MAT Credit Entitlement	-	-	-	-
9	Net Profit / (Loss) for the Period (7-8)	32.79	64.69	3.71	75.07
10	Other Comprehensive Income				
	Remeasurement of defined benefit plans	-		-	-
	Prior Period Adjustments & Expenses				-
11	Total Comprehensive Income for the period (9+10)	32.79	64.69	3.71	75.07
12	Paid up Equity Share Capital (F. V. of Re. 1/- Each)	156.57	156.57	156.57	156.57
13	Other Equity excluding Revaluation Reserve	10.00	10.00	10.00	10.00
14	Earnings per Share (of Re. 1/- each) :				
	(a) Basic-Rs	2.09	4.13	0.24	4.79
	(b) Diluted-Rs	2.09	4.13	0.24	4.79

NOTES:

- The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 06th Aug, 2022. The statutory auditors have carried out review of the results for the quarter ended June 30, 2022 and have expressed an unqualified audit opinion.
- The figures for the previous period/year have been regrouped /reclassified, wherever necessary.
- This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- The Disclosure is as per Regulation 33 of SEBI (Listing Obligations & Discloser Requirements) Regulations, 2015.
- The Company is operating in single segment, so above results are for single segment only.

Date: 06-08-2022

Place: Ahmedabad

FOR AND ON BEHALF OF BOARD OF DIRECTOR OF
SHUKRA PHARMACEUTICALS LIMITED

CIN : L24231GJ1993PLC019079


Bhoomiben Patel
AHMEDABAD
Bhoomiben Patel (Director)
DIN: 08316893

INDEPENDENT AUDITOR'S REVIEW REPORT on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors,
SHUKRA PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SHUKRA PHARMACEUTICALS LIMITED** (the "Company"), for the quarter ended June 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR MAAK and Associates
[Firm Registration No.135024W]
Chartered Accountants



Marmik Shah
Partner

Mem. No. 133926
UDIN : 22133926AOKUGC3827



Place : Ahmedabad
Date : 06-08-2022